Documents or data files from May 2022 often contain results from the trial, which evaluated TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism. Key findings shared around this time included:
The medical context for PTH at that time was dominated by the results of the clinical trial, which presented significant long-term efficacy and safety data in mid-2022. 2022 05 13 PTh actualizat.rar
If this file is a laboratory or reference update, it likely addresses the ongoing challenges in : Documents or data files from May 2022 often
Below is a review of the likely clinical findings and relevance associated with PTH updates from that period: 2022 05 13 PTh actualizat.rar